SEC Form 4 · accession 0000899243-17-028063

Calithera Biosciences, Inc. · CALA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — PRESIDENT AND CEO · Director

Period of report

Dec 5, 2017

Accepted (ET)

Dec 6, 2017 · 4:05 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001496671

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Dec 5, 2017	M	7,568	$0.96	A	10,068	D
Common Stock^F1	Dec 5, 2017	M	5,300	$2.64	A	15,368	D
Common Stock^F2	holding	—	—		—	349,190	I	By Trust
Common Stock	holding	—	—		—	11,702	I	By Spouse

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F3	$0.96	Dec 5, 2017	M	7,568	D	—	May 22, 2023	Common Stock	7,568	0	D
Employee Stock Option (Right to Buy)^F4	$2.64	Dec 5, 2017	M	5,300	D	—	Dec 16, 2023	Common Stock	5,300	34,030	D
Employee Stock Option (Right to Buy)^F3	$0.96	Dec 5, 2017	M	6,502	D	—	May 22, 2023	Common Stock	6,502	0	I
Employee Stock Option (Right to Buy)^F4	$2.64	Dec 5, 2017	M	2,700	D	—	Dec 16, 2023	Common Stock	2,700	6,006	I

F1Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on June 9, 2017.
F2Shares are held by the Molineaux Family Trust, of which the Reporting Person is a Trustee, including 23,810 shares transferred from the Reporting Person to the Molineaux Family Trust on March 30, 2017.
F31/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
F41/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.